Cell gene therapy: clinical trial application procedure of CAR-T therapy in the EU



Innovative therapies, such as Chimeric antigen receptor T-cell (CAR-T), are regulated in the European Union (EU) via the centralised procedure. However, national requirements on genetically modified organisms (GMO) apply and can vary among EU member states (MS). This article provides a short explanation on GMO and CAR-T therapy in the EU and gives a high-level overview of the requirements regarding clinical trial applications involving CAR-T products in the EU. One of the main concerns of regulators is the long-term safety of CAR-T products. With the development of label extension of CAR-T, Europe will probably adapt the regulatory framework to enhance the approval procedure of clinical trials with CAR-T.


How to read this journal article 

Thank you for visiting Regulatory Rapporteur. Journal articles are restricted to registered users and TOPRA members.

Already a member or have an account? Sign in.


Free access to selected content

Register to continue to access industry news, editorials and podcasts plus one member-only journal article each month.

  • Create your own library to save your favourite content.
Create a free account

2. Members login

Already a TOPRA member?

Log-in now using your MyTOPRA credentials, for unlimited access to all Regulatory Rapporteur journal articles, the online archive and latest industry news and podcasts.



TOPRA membership

Become a TOPRA member and join our global regulatory affairs community.

  • Great savings on our events and training.
  • Be part of our dynamic international community.
  • Contribute to the profession.
  • Grow your skills and knowledge.
  • Take your career to the next level.
Become a member